• MagicCube

  Participated · Equity · Jan 2026

  MagicCube develops a Software Defined Trust platform that secures payments, digital identities, and AI-driven services across smartphones, tablets, vehicles, self-checkout kiosks, and IoT devices without relying on hardware security components. Its platform is designed to operate across clouds, devices, and jurisdictions, giving governments, banks, and enterprises control over how and where critical data and AI models are protected. MagicCube positions itself as a neutral, hardware-independent trust layer to support regulatory compliance and operational resilience across borders. The company highlights relevance as sovereign funds, telecoms, and hyperscalers invest in next-generation compute infrastructure, particularly as the Gulf region emerges as a hub for AI and digital innovation. Strategic investors include Verifone, Bold Capital Partners, Mosaik Partners, and e& Capital. MagicCube is headquartered in Cupertino, California.

• Aqtual

  Participated · Series B · Jul 2025

  Aqtual’s core product is a proprietary active chromatin cfDNA platform that integrates DNA, epigenetic regulation, and protein–DNA binding into a single blood-based assay to quantify tissue-specific gene regulation. The platform profiles disease biology, microenvironment, and systemic immune response from cell-free DNA fragments to enable real-time analysis of disease and treatment. Aqtual is advancing a flagship therapy-response prediction test in rheumatoid arthritis and is actively enrolling patients in the PRIMA-102 prospective observational clinical trial (more than 1,300 patients enrolled; expected completion Q4 2025). The company plans to present new data and its commercialization plans at major rheumatology and diagnostics meetings in the second half of 2025. Financially, Aqtual recently completed an oversubscribed $31 million Series B, with participation from new and previous investors and additional capital from a strategic diagnostics partner. The funding is positioned to advance the internal pipeline and support near-term commercialization efforts. Aqtual develops a proprietary cell-free DNA platform that analyzes previously unexplored circulating DNA fragments to evaluate protein regulation, epigenetics, and transcriptomics. The platform catalogs regulatory features at high resolution, including roughly 200,000 gene promoters, 400,000 enhancers, 50,000 insulators, 20,000 silencers, and 1 million transcription factor binding sites. Aqtual says this approach provides an order-of-magnitude greater detail into gene regulation than other cell-free DNA methods and can support diagnostics and drug-discovery applications. The company has initiated PRIMA-102, a prospective multi-center clinical trial (NCT05936970) in rheumatoid arthritis and has enrolled the first patient; the study plans to enroll 150 individuals to develop a classifier that predicts effective drug classes. Aqtual plans to use the assay to help physicians select the best treatments for rheumatoid arthritis patients and to expand applications across major disease areas. The company highlights potential for improved treatment decisions, faster selection of effective therapies, and new roadmaps for drug development.

• Mighty Buildings

  Led · Equity · Sep 2023

  Mighty Buildings develops 3D-printed, prefab kits and factory-built components for residential construction, using a proprietary material made of 60% recycled glass. The company manufactures parts off-site using ultraviolet curing and microfactories to enable rapid, repeatable production and automotive-grade quality control. Its printed material is described as stronger and lighter than concrete, rated for winds up to 150 mph, and compliant with California building codes including Title 24 energy requirements. Mighty shifted from selling homes directly to selling whole communities and kits to developers, aiming for larger-scale projects. The company reported roughly $5 million in revenue in 2022 and says it has a pipeline of projects in the U.S., Caribbean and Middle East potentially worth “hundreds of millions.” Mighty Buildings, based in Oakland, CA, develops construction technologies that combine 3D printing, robotics, and advanced composite materials to create panelized building systems and modular homes. The company produces a range of projects from pre-designed ADUs to single-family developments using its Mighty Kit System. Mighty Buildings is building a network of micro-factories intended to produce 200–300 homes per year in locations with housing gaps. Leadership includes CEO Slava Solonitsyn and Chief Sustainability Officer Sam Ruben. The company is pursuing a carbon neutrality roadmap that emphasizes high-throughput sustainable micro-factories, strategic supply-chain partnerships, blue-skies technology research, and new composite materials made from recycled or bio-based feedstock. As of the article, Mighty Buildings had raised a total of $100M to date. Mighty Buildings is an Oakland-based construction technology company that 3D-prints prefabricated homes and accessory dwelling units using robotics, automation and a proprietary thermoset composite called Light Stone Material (LSM). The company says its process can 3D print a 350-square-foot studio in 24 hours, operate two times faster with 95% less labor hours and produce 10-times less waste than conventional construction, and automate up to 80% of the construction process through robotic post-processing and automated insulation pouring. It manufactures panelized 3D-printed exterior shells and prefabricates certain modules (like bathrooms) in a 79,000-square-foot Oakland production facility and is currently building only in California. Mighty Houses, its single-family product line, ranges from 864 to 1,440 square feet with estimated prices of $304,000 to $420,500, and the company has produced and installed a number of ADUs and secured developer contracts. The company plans to scale production capacity and automation with the new capital, market a Mighty Kit System and a new fiber-reinforced material for multi-story projects, and develop a B2B platform to offer production-as-a-service to builders and developers. Mighty Buildings launched out of stealth last August, is a four-year-old startup and has been included on Y Combinator’s Top Companies list; the company declined to reveal its current valuation. Mighty Buildings provides a production-as-a-service platform that combines 3D printing and prefab techniques to automate up to 80% of the building process. Its factory-driven approach can 3D-print components, panels, and full-size volumetric modules, and a 350-square-foot studio unit can be printed in under 24 hours. The company reports building with 95% fewer labor hours, at double the speed of conventional construction, and producing 10x less waste; its homes cost up to 45% less than comparable traditional homes, with automated production costs 20–30% lower than traditional prefab. Mighty Buildings is certified under California’s Factory Built Housing program and was first to achieve UL 3401 certification for 3D-printed building structures and assemblies. It has installed its first two accessory dwelling units in San Ramon and San Diego and says it is ready to scale production. The company graduated from Y Combinator in winter 2018 and is launching out of stealth from San Francisco.

• Viome Life Sciences

  Participated · Series C · Aug 2023

  Viome Life Sciences, based in Bellevue, WA and led by Founder and CEO Naveen Jain, focuses on longevity and preventative healthcare. The company leverages AI and algorithms to analyze gene expression data from over 600,000 samples to power at-home tests and personalized recommendations. Its product lineup includes custom-formulated supplements unique to each individual, personalized biotic blends for gut health, and oral biotic lozenges for oral microbiome health. Viome intends to deploy new capital toward research and development and retail expansion. Financially, it has raised a total of $175M to date after closing an $86.5M Series C. Investors in the most recent round include Khosla Ventures, Bold Capital, WRG Ventures and others. Viome Life Sciences is a Bellevue, WA-based systems biology company that uses biological data to help individuals improve their health. The company positions itself around systems-biology approaches to personalized health. Public reporting emphasizes its aim to translate biological insights into health-improvement offerings. Financially, Viome has been an active fundraiser, most recently securing a $54M pre-Series C convertible round. This follows a $56M Series B announced in November 2019 and brings total funding to date to over $125M. Returning and new investor participation has supported its continued operations and product development efforts.

• Viome

  Led · Series C · Aug 2023

  Viome combines RNA sequencing, epigenetic biomarker analysis, and artificial intelligence to deliver personalized nutritional guidance, microbiome products, and diagnostics such as its CancerDetect™ test. The CancerDetect™ test is reported to have 90% sensitivity and 95% specificity and has received the FDA Breakthrough Device Designation. The company says it has empowered over half a million users with its AI-driven health insights and offers custom-formulated supplements and probiotics alongside its testing. Viome is expanding into a diagnostics division and plans broader diagnostic capabilities including gut-health assays. Leadership has been strengthened with the appointment of Kal Raman as COO to help scale operations and accelerate the company’s diagnostic and product roadmap. The company also reports a collaboration with GlaxoSmithKline to study the gut microbiome’s link to chronic disease. Viome assesses customers' microbiomes using RNA sequencing and AI to generate personalized nutritional and supplement recommendations. Its product suite includes tests based on blood, stool and saliva, tailored vitamin supplements and diet assessments. The company says its RNA gene-expression technology was developed from Los Alamos research, is clinically validated and exclusively licensed to analyze biological samples at much greater scale than other technologies. Viome reports it has run tests for about 350,000 consumers from 106 countries (roughly 600,000 samples) and claims more than 52 petabytes of sequencing plus clinical metadata powering over 35 predictive models of chronic disease. It also says it holds an FDA breakthrough device designation for saliva-based early-stage mouth and throat cancer detection with ~95% specificity and >90% sensitivity. Viome plans to use the new equity funding to expand existing offerings, launch mouth and dental-health product lines, and pursue retail partnerships such as a deal to sell tests in roughly 200 CVS stores. The company has also faced criticism from some scientists who say certain public claims are misleading. Viome analyzes customers' microbiomes via stool samples and uses RNA sequencing technology (originating from Los Alamos National Laboratory) combined with machine-learning algorithms to generate personalized food recommendations and predict bodily responses to foods. The company says it is running clinical studies across roughly 15 separate diseases — from insomnia to pancreatic cancer — with the stated aim of predicting, preventing and reversing chronic diseases including diabetes, autoimmune disorders, Parkinson’s and some cancers. Viome plans to use the new funding to expand that research and its clinical programs. The company recently acquired personalized nutrition service Habit from Campbell Soup for an undisclosed sum. Viome has nearly 150 employees across six locations, including its headquarters in Bellevue, Wash., and offices in San Diego, Santa Clara, New York, Bangalore and Los Alamos, N.M. Its claims have attracted both prominent endorsements (Deepak Chopra, Dr. Mehmet Oz, Dr. Mark Hyman) and public scientific criticism questioning the state of the underlying science. Viome uses proprietary technology licensed from the Los Alamos National Laboratory to identify and quantify microorganisms in the gut and analyze their activity. By applying machine learning to these molecular profiles, it generates personalized nutritional recommendations intended to balance the microbiome and help prevent chronic illnesses. The company plans to use the new funding to launch an at-home health kit focused on the microbiome and to expand market availability. Viome is operating an early beta with several thousand customers and has 45 employees across Cupertino, Los Alamos, and New York. The firm raised $15M in a Series A, bringing total funding to $21M. Leadership includes CEO Naveen Jain, CTO Guruduth Banavar, and CSO Momo Vuyisich, and the company lists several health and longevity figures as ambassadors.

No current team members are available.